Martínez Granero M A, Garcia Pérez A, Martínez-Pardo M, Parra E
Servicio de Pediatría, Fundación Hospital Alcorcón, Madrid, Spain.
Neurologia. 2005 Jun;20(5):255-60.
The clinical manifestations of glutaric aciduria type I (GA-I) usually develop during the first two years of life as acute encephalopathic crisis leading to irreversible dystonic. Progressive macrocephaly can be an early clinical sign. We report a 9 month old patient with macrocephaly diagnosed of GA-I in the presyntomatic stage. This early diagnosis and treatment avoided the irreversible neurologic damage associated to this disease.
A 9 month old male referred to the pediatrics neurology clinic because of macrocephaly with a head circumference of 51 cm (> 97th percentle). At birth this head circumference was 37.5 cm (97th percentile) and showed rapid growth during the first 4 months of life. In the physical exam there was mild hypotonia and no other neurologic alterations with normal psychomotor development. In the work up for macrocephaly urinary organic acids were determined showing a glutaric acid: 78,000 mmol/mol creatinine (normal values: 2-10); 3-hydroxyglutaric acid: 250 mmol/mol creatinine (normal values: 1-12). Cerebral magnetic resonance (MR) performed at 12 months of age showed frontotemporal atrophy with enlargement of subarachnoid spaces, a high signal in T2 in the pallidus nucleus and subdural hematomas. Genetic analysis showed a mutation S 305 L/Q 352 X in GCDH gene. L-carnitine and riboflavin supplementation and a diet with restriction of lysine and tryptophan was started. Intercurrent illnesses were treated with intravenous fluid, glucose and L-carnitine. At 3 years and 6 month of age, he had not shown any encephalopathic crisis, he had a normal psychomotor development and no dystonia. MR shows mild temporal lobe atrophy without basal ganglia alterations.
In GA-I, macrocephaly is an early sign before other neurologic alterations. In patients with little or no neurological symptoms, early treatment may prevent the acute encephalopathic crisis and neurological deterioration, improving the prognosis and may also normalize the basal ganglia neuroradiological alterations. Urinary organic acid analysis should be performed in the work up of macrocephaly of unknown aetiology.
I型戊二酸血症(GA-I)的临床表现通常在生命的头两年出现,表现为急性脑病危机,导致不可逆的肌张力障碍。进行性巨头症可能是早期临床症状。我们报告一名9个月大的患者,在症状前期被诊断为GA-I并伴有巨头症。这种早期诊断和治疗避免了与该疾病相关的不可逆神经损伤。
一名9个月大的男性因巨头症被转诊至儿科神经科门诊,头围为51厘米(>第97百分位)。出生时头围为37.5厘米(第97百分位),在生命的前4个月内迅速增长。体格检查显示轻度肌张力减退,无其他神经改变,精神运动发育正常。在对巨头症的检查中,测定了尿有机酸,结果显示戊二酸:78,000 mmol/mol肌酐(正常值:2 - 10);3-羟基戊二酸:250 mmol/mol肌酐(正常值:1 - 12)。12个月大时进行的脑磁共振成像(MR)显示额颞叶萎缩,蛛网膜下腔增宽,苍白球核T2加权像呈高信号以及硬膜下血肿。基因分析显示GCDH基因存在S 305 L/Q 352 X突变。开始补充左旋肉碱和核黄素,并采用限制赖氨酸和色氨酸的饮食。并发疾病通过静脉补液、葡萄糖和左旋肉碱进行治疗。在3岁6个月时,他未出现任何脑病危机,精神运动发育正常,无肌张力障碍。MR显示轻度颞叶萎缩,无基底节改变。
在GA-I中,巨头症是在其他神经改变之前的早期症状。对于几乎没有或没有神经症状的患者,早期治疗可能预防急性脑病危机和神经功能恶化,改善预后,还可能使基底节神经放射学改变恢复正常。对于病因不明的巨头症检查应进行尿有机酸分析。